A new Phase 2 clinical trial is shining a spotlight on the potential benefits of Zabopegdutide for MASH patients. HistoIndex’s AI-powered analysis has revealed robust improvements in liver fibrosis, offering a promising glimpse of future treatment possibilities.

A transformative partnership between Lunit and Labcorp promises to accelerate digital pathology innovations through artificial intelligence. By combining Lunit’s expertise in AI-driven cancer diagnostics with Labcorp’s extensive laboratory services, the collaboration aims to support new breakthroughs in oncology research and clinical care.